Additionally, ARID2 reduction hastens the G1/S transition, which was also coupled with increased levels of cyclin D1, cyclin E1, CDK4 and retinoblastoma protein phosphorylation (Rb), suggesting that ARID2 suppresses hepatoma cell-cycle advancement and tumourigenesis by targeting the Rb-E2F signalling pathway [151]. The gene discussed is ARID2; the disease is hepatocellular carcinoma.